PortalPublikationenPOEMS syndrome treated with melphalan high-dose therapy and ...

POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience

Standard

POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience. / Thoennissen, Gabriela B; Thoennissen, Nils H; Fritz, Fleur; Hilbig, Andreas; Kerkhoff, Andrea; Liersch, Ruediger; Krug, Utz; Koschmieder, Steffen; Müller-Tidow, Carsten; Mesters, Rolf; Kropff, Martin; Berdel, Wolfgang E.

in: ANN HEMATOL, Jahrgang 91, Nr. 9, 09.2012, S. 1419-25.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Thoennissen, GB, Thoennissen, NH, Fritz, F, Hilbig, A, Kerkhoff, A, Liersch, R, Krug, U, Koschmieder, S, Müller-Tidow, C, Mesters, R, Kropff, M & Berdel, WE 2012, 'POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience', ANN HEMATOL, Jg. 91, Nr. 9, S. 1419-25. https://doi.org/10.1007/s00277-012-1473-7

APA

Thoennissen, G. B., Thoennissen, N. H., Fritz, F., Hilbig, A., Kerkhoff, A., Liersch, R., Krug, U., Koschmieder, S., Müller-Tidow, C., Mesters, R., Kropff, M., & Berdel, W. E. (2012). POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience. ANN HEMATOL, 91(9), 1419-25. https://doi.org/10.1007/s00277-012-1473-7

Vancouver

Thoennissen GB, Thoennissen NH, Fritz F, Hilbig A, Kerkhoff A, Liersch R et al. POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience. ANN HEMATOL. 2012 Sep;91(9):1419-25. https://doi.org/10.1007/s00277-012-1473-7

Bibtex

@article{af370e7fd269410f8023523fc3e0d49a,
title = "POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience",
abstract = "The acronym POEMS syndrome stands for a rare multi-system disorder, comprised of polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes. Here, we present a single-center report of a series of five POEMS patients treated with melphalan high-dose therapy (HDT) with subsequent autologous blood stem cell transplantation (ABSCT). After a median follow-up of 52 months from time of diagnosis (range, 15-192) and a median follow-up of 18 months after ABSCT (range, 11-120), all patients were alive. Overall, no severe transplantation-associated complications such as engraftment syndrome or peri- or post-transplant death were noted. In two cases, HDT followed by ABSCT resulted in a complete hematologic response; in the additional three cases, partial responses (PR) were achieved including one very good hematologic PR. Only one patient with initial PR developed progressive disease nearly 2.5 years after transplantation. Consequently, a second HDT with ABSCT was successfully applied resulting in clinical improvement and hematologic PR. In line with previous single-center reports, melphalan HDT followed by ABSCT proved to be a first-line treatment option with tolerable side effects in severely affected POEMS patients with progressing symptoms.",
keywords = "Adult, Anthracyclines, Combined Modality Therapy, Dexamethasone, Female, Humans, Male, Melphalan, Middle Aged, Myeloablative Agonists, Neurologic Examination, POEMS Syndrome, Peripheral Blood Stem Cell Transplantation, Transplantation, Autologous, Treatment Outcome, Vascular Endothelial Growth Factor A",
author = "Thoennissen, {Gabriela B} and Thoennissen, {Nils H} and Fleur Fritz and Andreas Hilbig and Andrea Kerkhoff and Ruediger Liersch and Utz Krug and Steffen Koschmieder and Carsten M{\"u}ller-Tidow and Rolf Mesters and Martin Kropff and Berdel, {Wolfgang E}",
year = "2012",
month = sep,
doi = "10.1007/s00277-012-1473-7",
language = "English",
volume = "91",
pages = "1419--25",
journal = "ANN HEMATOL",
issn = "0939-5555",
publisher = "Springer",
number = "9",

}

RIS

TY - JOUR

T1 - POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience

AU - Thoennissen, Gabriela B

AU - Thoennissen, Nils H

AU - Fritz, Fleur

AU - Hilbig, Andreas

AU - Kerkhoff, Andrea

AU - Liersch, Ruediger

AU - Krug, Utz

AU - Koschmieder, Steffen

AU - Müller-Tidow, Carsten

AU - Mesters, Rolf

AU - Kropff, Martin

AU - Berdel, Wolfgang E

PY - 2012/9

Y1 - 2012/9

N2 - The acronym POEMS syndrome stands for a rare multi-system disorder, comprised of polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes. Here, we present a single-center report of a series of five POEMS patients treated with melphalan high-dose therapy (HDT) with subsequent autologous blood stem cell transplantation (ABSCT). After a median follow-up of 52 months from time of diagnosis (range, 15-192) and a median follow-up of 18 months after ABSCT (range, 11-120), all patients were alive. Overall, no severe transplantation-associated complications such as engraftment syndrome or peri- or post-transplant death were noted. In two cases, HDT followed by ABSCT resulted in a complete hematologic response; in the additional three cases, partial responses (PR) were achieved including one very good hematologic PR. Only one patient with initial PR developed progressive disease nearly 2.5 years after transplantation. Consequently, a second HDT with ABSCT was successfully applied resulting in clinical improvement and hematologic PR. In line with previous single-center reports, melphalan HDT followed by ABSCT proved to be a first-line treatment option with tolerable side effects in severely affected POEMS patients with progressing symptoms.

AB - The acronym POEMS syndrome stands for a rare multi-system disorder, comprised of polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes. Here, we present a single-center report of a series of five POEMS patients treated with melphalan high-dose therapy (HDT) with subsequent autologous blood stem cell transplantation (ABSCT). After a median follow-up of 52 months from time of diagnosis (range, 15-192) and a median follow-up of 18 months after ABSCT (range, 11-120), all patients were alive. Overall, no severe transplantation-associated complications such as engraftment syndrome or peri- or post-transplant death were noted. In two cases, HDT followed by ABSCT resulted in a complete hematologic response; in the additional three cases, partial responses (PR) were achieved including one very good hematologic PR. Only one patient with initial PR developed progressive disease nearly 2.5 years after transplantation. Consequently, a second HDT with ABSCT was successfully applied resulting in clinical improvement and hematologic PR. In line with previous single-center reports, melphalan HDT followed by ABSCT proved to be a first-line treatment option with tolerable side effects in severely affected POEMS patients with progressing symptoms.

KW - Adult

KW - Anthracyclines

KW - Combined Modality Therapy

KW - Dexamethasone

KW - Female

KW - Humans

KW - Male

KW - Melphalan

KW - Middle Aged

KW - Myeloablative Agonists

KW - Neurologic Examination

KW - POEMS Syndrome

KW - Peripheral Blood Stem Cell Transplantation

KW - Transplantation, Autologous

KW - Treatment Outcome

KW - Vascular Endothelial Growth Factor A

U2 - 10.1007/s00277-012-1473-7

DO - 10.1007/s00277-012-1473-7

M3 - SCORING: Journal article

C2 - 22543828

VL - 91

SP - 1419

EP - 1425

JO - ANN HEMATOL

JF - ANN HEMATOL

SN - 0939-5555

IS - 9

ER -